PREP/PP2A Modulator Program
Frontotemporal Dementia (FTD)
Key Facts
About Polku Therapeutics
Polku Therapeutics is a preclinical-stage biotech pioneering a novel approach to treating neurodegenerative diseases by modulating the PREP-PP2A protein-protein interaction axis. Its platform yields small molecules designed to induce autophagy, dephosphorylate tau, and reduce inflammation, addressing key pathological drivers in conditions like frontotemporal dementia and Parkinson's disease. The company, spun out from University of Helsinki research, has secured €2.7M in pre-seed funding and is advancing a capital-efficient pipeline strategy, initially targeting orphan tauopathies. Leadership combines deep academic expertise in neuropharmacology and medicinal chemistry with seasoned biopharma business development experience.
View full company profileAbout Polku Therapeutics
Polku Therapeutics is a preclinical-stage biotech pioneering a novel approach to treating neurodegenerative diseases by modulating the PREP-PP2A protein-protein interaction axis. Its platform yields small molecules designed to induce autophagy, dephosphorylate tau, and reduce inflammation, addressing key pathological drivers in conditions like frontotemporal dementia and Parkinson's disease. The company, spun out from University of Helsinki research, has secured €2.7M in pre-seed funding and is advancing a capital-efficient pipeline strategy, initially targeting orphan tauopathies. Leadership combines deep academic expertise in neuropharmacology and medicinal chemistry with seasoned biopharma business development experience.
View full company profileAbout Polku Therapeutics
Polku Therapeutics is a preclinical-stage biotech pioneering a novel approach to treating neurodegenerative diseases by modulating the PREP-PP2A protein-protein interaction axis. Its platform yields small molecules designed to induce autophagy, dephosphorylate tau, and reduce inflammation, addressing key pathological drivers in conditions like frontotemporal dementia and Parkinson's disease. The company, spun out from University of Helsinki research, has secured €2.7M in pre-seed funding and is advancing a capital-efficient pipeline strategy, initially targeting orphan tauopathies. Leadership combines deep academic expertise in neuropharmacology and medicinal chemistry with seasoned biopharma business development experience.
View full company profileAbout Polku Therapeutics
Polku Therapeutics is a preclinical-stage biotech pioneering a novel approach to treating neurodegenerative diseases by modulating the PREP-PP2A protein-protein interaction axis. Its platform yields small molecules designed to induce autophagy, dephosphorylate tau, and reduce inflammation, addressing key pathological drivers in conditions like frontotemporal dementia and Parkinson's disease. The company, spun out from University of Helsinki research, has secured €2.7M in pre-seed funding and is advancing a capital-efficient pipeline strategy, initially targeting orphan tauopathies. Leadership combines deep academic expertise in neuropharmacology and medicinal chemistry with seasoned biopharma business development experience.
View full company profileTherapeutic Areas
Other Frontotemporal Dementia (FTD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Neuro-Cells® | Neuroplast | Preclinical/Phase 1 |
| COYA 302 | Coya Therapeutics | Phase 2 |